Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); 2012 Preview
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.
Needham analyst says, "Optimer launched Dificid in the U.S. in July 2011 for the treatment of C. difficile infection and announced $10.6M in U.S. sales in 3Q11. The drug was approved in Europe in December 2011, with launch expected by collaborator Astellas in that territory early this year. We expect this to trigger up to €50M in milestone payments in 1H12. Other expected key milestones for the company in 2012 include potential approval/launch in Canada, expansion from the hospital into long-term care facility markets, and initiation of Phase 4 label expansion trials. We believe the stock is undervalued ($430M EV), given the unmet need in C. difficile and superiority over pre-existing agents, including vancomycin and metronidazole."
"We believe Optimer will move forward with Phase 4 label expansion trials in 2012. Management has suggested that it plans to conduct a trial in patients undergoing stem cell transplant to investigate potential for prophylaxis. Trials in certain subpopulations, including pediatric, are also planned."
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.14 yesterday.
Needham analyst says, "Optimer launched Dificid in the U.S. in July 2011 for the treatment of C. difficile infection and announced $10.6M in U.S. sales in 3Q11. The drug was approved in Europe in December 2011, with launch expected by collaborator Astellas in that territory early this year. We expect this to trigger up to €50M in milestone payments in 1H12. Other expected key milestones for the company in 2012 include potential approval/launch in Canada, expansion from the hospital into long-term care facility markets, and initiation of Phase 4 label expansion trials. We believe the stock is undervalued ($430M EV), given the unmet need in C. difficile and superiority over pre-existing agents, including vancomycin and metronidazole."
"We believe Optimer will move forward with Phase 4 label expansion trials in 2012. Management has suggested that it plans to conduct a trial in patients undergoing stem cell transplant to investigate potential for prophylaxis. Trials in certain subpopulations, including pediatric, are also planned."
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Pulse Biosciences (PLSE) at Buy
- Deutsche Bank Downgrades Netskope (NTSK) to Hold on Valuation
- BWS Financial Downgrades Inter Parfums (IPAR) to Sell
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
